Skip to the reading
KLOW Ordinary

The KLOW peptide references keep the setting attached.

Here are the sources cited in this guide. The paper titles are linked in full, with a short note about what was tested. You don’t need to read every paper to see where the limits lie.

Surface closure in rats

Malinda KM, et al. — “Thymosin beta4 accelerates wound healing” (1999).

Full thymosin beta-4 helped wounds become covered again in rats. This was an animal experiment, not a KLOW result in people.

An injured tendon in rats

Staresinic M, et al. — “Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth” (2003).

BPC-157 was studied in injured rat Achilles tendons. A tendon result doesn’t establish a benefit for human skin or for the blend.

Inflammatory signals in cells and mice

Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D — “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation” (2008).

Cell and mouse work on intestinal inflammation. It helps explain interest in KPV without establishing that KLOW helps skin repair.

A review of GHK and skin

Pickart L, Vasquez-Soltero JM, Margolina A — “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration” (2015).

A review of lab findings and small topical studies. Its summaries concern those preparations, not injections of the four-part blend.

Copper passing through skin samples

Hostynek JJ, Dreher F, Maibach HI — “Human skin penetration of a copper tripeptide in vitro as a function of skin layer” (2011).

Copper was measured in human skin samples in a lab. The study didn’t measure healing in people or test the KLOW mixture.

Full thymosin beta-4 in volunteers

Ruff D, et al. — “A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers” (2010).

Healthy volunteers received the full protein into a vein. This is the source of the study amounts on the dosage page; it wasn’t TB-500.

A very small BPC-157 safety observation

Lee E, Burgess K — “Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study” (2025).

Just two adults received BPC-157 into a vein. No reported adverse events in that small group can’t establish the safety of KLOW.

Vessel-growth signalling

Hsieh MJ, et al. — “Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation” (2017).

Cell and animal work on blood-vessel growth. It helps explain a theoretical cancer concern, rather than demonstrating cancer risk from KLOW.

FDA component safety concerns

FDA — Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.

The page is current as of April 22, 2026. Withdrawn nominations retain safety concerns; only GHK-Cu’s injectable entry carries that route qualifier.

What compounded status means

FDA — Compounding and the FDA: Questions and Answers.

FDA explains that compounded medicines are not FDA-approved. A prescription decision and approval are different things.

What these sources can answer

None of these papers tests the actual four-part KLOW combination. Each source has its own substance, route and setting. That’s why the notes keep those details close.

The home page puts the repair terms into everyday language. This guide can explain a finding, but it can’t assess your skin or make a personal treatment decision.